whoa. whoa. whoa.

You're being directed to the ELOCTATE Healthcare Professional website. If you're okay with that, we're okay with that.

Come back soon!

+

Please see full Prescribing Information.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

What is the most important information I need to know about ALTUVIIIO?

Do not attempt to give yourself an injection unless you have been taught how by your healthcare provider or hemophilia center. You must carefully follow your healthcare provider's instructions regarding the dose and schedule for injecting ALTUVIIIO so that your treatment will work best for you.

Who should not use ALTUVIIIO?

You should not use ALTUVIIIO if you have had an allergic reaction to it in the past.

What should I tell my healthcare provider before using ALTUVIIIO?

Tell your healthcare provider if you have had any medical problems, take any medications, including prescription and non-prescription medicines, supplements, or herbal medicines, are breastfeeding, or are pregnant or planning to become pregnant.

What are the possible side effects of ALTUVIIIO?

You can have an allergic reaction to ALTUVIIIO. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

The common side effects of ALTUVIIIO are headache, joint pain, and back pain.

These are not the only possible side effects of ALTUVIIIO. Tell your healthcare provider about any side effect that bothers you or does not go away.

INDICATION

ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ALTUVIIIO when you have surgery.

Sanofi logo

© 2024 Genzyme Corporation. All rights reserved. ALTUVIIIO and Sanofi are trademarks of Sanofi or an affiliate.

MAT-US-2209700-v2.0-07/2023

Some see a gearhead. We see the nearly We see the nearly 60 joints performing every tune up

ELOCTATE Prophylaxis Offers Bleed Protection* You Can Count On.

Jonathan Car

BLEED AND JOINT BLEED PROTECTION* YOU CAN COUNT ON

Preventing bleeds and joint bleeds allows you to get back to all the things you love to do.

(SELECT ONE)

Adults
(12 years and older)
Children
(under 12 years old)

Facts About Bleed Protection


In clinical studies of adults and adolescents using an individualized prophylaxis regimen:

1.6 median annual overall bleeds per year
Median of Zero Joint Bleeds Per Year
About 100% of Target Joints Resolved*

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

In the A-LONG study, 164 adults and adolescents ages 12-65 received ELOCTATE either every 3 to 5 days, once weekly, or on demand.

The ASPIRE extension study included 150 people who completed A-LONG. Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or fewer spontaneous bleeds in a 12-month period.

GET RELIEF. GET CONTROL.


In a clinical study of adults and adolescents treating on demand:

In 8 out of 10 bleeding episodes patients saw pain relief and/or improvement in signs of bleeding with 1 infusion. (n=582)
87% of bleeds were controlled with 1 infusion. (n=661)

On-demand treatment and control of bleed episodes

+


Photo of Kenny, an ELOCTATE Peer

I'm happy with the bleed and joint bleed protection I'm getting from my ELOCTATE prophy. And that's important to me.

- Kenny, an ELOCTATE PEER

Note: This is a personal account of an ELOCTATE Peer. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary. ELOCTATE Peers have been compensated for sharing their stories.

Dosing That Lets You Do You

In clinical trials, 98.8% of patients were able to dose less frequently with ELOCTATE than with their prior standard half-life treatment.

With a variety of vial strength options, ELOCTATE offers individualized dosing and the potential for fewer infusions using a prophylaxis regimen.

See How We Stack Up

In clinical studies, ELOCTATE was shown to last 50% longer in the body than ADVATE®. Learn how extended half-life dosing made a difference for DJ.

GO TO DJ'S STORY

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.

Most patients were able to dose less frequently with Eloctate than with their prior standard half-life treatment

Fc Fusion and You

Fc Fusion utilizes naturally occurring Fc receptors in your body to keep Factor VIII temporarily recirculating in your bloodstream.2-6 ELOCTATE is Factor VIII fused with an Fc protein. For the scientist in you, check out this video with a little more detail about how Fc Fusion works.

Contact your CoRe

Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.

Get informed. Stay informed.

Let's stay in touch. We'll occasionally send you important information on Hemophilia A and ELOCTATE.

LET'S GET STARTED

IMPORTANT SAFETY INFORMATION AND INDICATIONS

+

IMPORTANT SAFETY INFORMATION

Do not use ELOCTATE if you have had an allergic reaction to it in the past.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.

Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.

Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.

Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.

If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.

These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.

INDICATIONS

ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.

PLEASE SEE FULL PRESCRIBING INFORMATION

MANUFACTURED BY

Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078

CLICK HERE TO LEARN MORE ABOUT SANOFI'S COMMITMENT TO FIGHTING COUNTERFEIT DRUGS.